Most Down Articles

Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|

Most Downloaded in Recent Year

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Electronic Journal of Liver Tumor    2023, 10 (4): 1-14.   Abstract （296）      PDF （2280KB）（260）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association; Chinese Society of Liver Cancer, Chinese Anti-Cancer Association; Liver Study Group of Surgery Committee of Beijing Medical Association; Editorial Board of Chinese Journal of Hepatobiliary Surgery Electronic Journal of Liver Tumor    2021, 8 (2): 6-15.   Abstract （414）      PDF （1752KB）（657）       Knowledge map    Save As many as half of hepatocellular carcinomas are at advanced stage when first diagnosed, and advanced stage hepatocellular carcinoma lacks effective treatment which leads to a very poor prognosis. In recent years, Immune checkpoint inhibitors combined with anti-angiogenesis drugs has shown a high effective rate in the treatment of advanced hepatocellular carcinoma, which significantly prolongs the overall survival of the patients and also provides the possibility of the sequent radical surgery? In order to improve the long-term survival rate of the liver cancer patients and achieve the goal of increasing the 5-year overall survival rate by 15% according to "Healthy China 2030" plan, the Hepatobiliary and Pancreatic Disease Prevention and Control Committee of the Chinese Preventive Medicine Association and the Liver Cancer Committee of the Chinese Anti-Cancer Association have deep discussions on the key points of medical treatment of advanced hepatocellular carcinoma and a preliminary consensus was formed to guide clinical practice, standardize medical behavior, and promote disciplines. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (3): 1-11.   Abstract （139）      PDF （1692KB）（249）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Global liver cancer and gallbladder cancer incidence and mortality in 2020 Shan Tianhao1, An Lan1, Xu Mengyuan1, Zeng Hongmei1,*, Cai Jianqiang2,* Electronic Journal of Liver Tumor    2022, 9 (4): 46-51.   Abstract （342）      PDF （2337KB）（190）       Knowledge map    Save Objective:According to the data of GLOBOCAN 2020, we compared the global and Chinese incidence and mortality of liver cancer and gallbladder cancer in 2020, to provide a scientific basis for cancer prevention and control. Method:According to the incidence and mortality data of liver cancer and gallbladder cancer released by the International Agency for Research on Cancer in 2020, the differences among different regions, genders and ages were compared. Result:In 2020, there were 905 677 new cases and 830 180 deaths of liver cancer globally, with age-standardized incidence and mortality rates of 9.5/100 000 and 8.7/100 000, respectively. For gallbladder cancer, the numbers of new cases and deaths were 115 949 and 84 695, respectively, with the age-standardized incidence and mortality of 1.2/100 000 and 0.84/100 000, respectively. The top five countries with highest incidence of liver cancer were Mongolia, Egypt, Laos, Cambodia and Vietnam. The top five countries with highest incidence of gallbladder cancer were Bolivia, Chile, Bangladesh, Nepal and Korea. In 2020, there were 410 038 new cases of liver cancer in China, with a standardized incidence rate of 18.2/100 000, ranking 8th among all countries. There were 391 152 new cases of death from liver cancer in China, with an age-standardized mortality rate of 17.2/100 000. For gallbladder cancer, there were 28 923 new cases of incidence in China, with an age-standardized incidence rate of 1.2/100 000, ranking 39th among all countries. There were 23 297 new cases of death from gallbladder cancer in China, with an age-standardized mortality rate of 0.97/100 000. Conclusion:The disease burden of liver cancer and gallbladder cancer is different between countries. Different prevention and control strategies should be formulated according to different populations. Reference | Related Articles | Metrics

Select

Research progress in immunotherapy and biomarkers for hepatocellular carcinoma Peng Xuenan, Zhou Aiping Electronic Journal of Liver Tumor    2020, 7 (4): 17-22.   Abstract （83）      PDF （1654KB）（359）       Knowledge map    Save The incidence of hepatocellular carcinoma (HCC) in China ranked fourth among all malignant tumors, and the mortality rate ranked second in 2015. Approximately 85% of Chinese patients are in the intermediate stage or advanced stage at the first visit and lose the best treatment chance. The 5-year survival rate of them is only 12%. Since 2007, treatments for advanced hepatocellular carcinoma mostly focused on targeted therapy, with limited efficacy. In recent years, immune checkpoint inhibitors have achieved 17% ~ 20% and 15% ~ 20% objective response rate in first-line and second-line monotherapy respectively. Immunotherapy shows obviously anti-tumor effect that is superior to traditional targeted therapy. Initial results have also achieved in the field of neoadjuvant and adjuvant therapy for HCC. However, several challenges such as treatment selection after disease progression and disease recurrence after liver transplantation are still unsolved. Exploring immune-specific biomarkers to predict the efficacy has also become an important direction in the field of immunotherapy. In this review, we summarized the research progress of immunotherapy and biomarkers for hepatocellular carcinoma. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (1): 65-69.   Abstract （57）      PDF （2314KB）（158）       Knowledge map    Save Related Articles | Metrics

Select

Clinical study on individualized medication of tacrolimus after liver transplantation guided by CYP3A5 gene polymorphism for hepatocellular carcinoma Jiang Tao, Pan Fei, Chen Qing, Huang Jincan, He Qiang, Lang Ren Electronic Journal of Liver Tumor    2021, 8 (3): 8-11.   Abstract （70）      PDF （1641KB）（119）       Knowledge map    Save Objective: To evaluate the safety and efficacy based on CYP3A5 gene polymorphisms in guiding the individualized tacrolimus therapy after liver transplantation for hepatocellular carcinoma. Methods: Clinical data of 120 patients with primary hepatocellular carcinoma were analyzed who underwent orthotopic liver transplantation from January 2018 to December 2019. According to whether the donor and recipient CYP3A5 gene was detected before operation, they were divided into individualized medication group and conventional medication group. The initial dose of tacrolimus was determined according to CYP3A5 genotype and previous experience in the two groups. The recovery rates of liver function at 14, 21, 28 days and 3, 6, 9, 12 months after operation were observed. The incidence of acute rejection, acute kidney injury, neurological symptoms, infection, de novo hypertension, de novo diabetes and the overall survival rate were recorded. Results: The differences of recovery rate of liver function between the two groups of recipients at 14 days and 21 days after was statistically significant (all P<0.05). There was no significant difference in the incidence of complications and overall 1-year and 2-year survival rates between the two groups (P> 0.05). Conclusion: It is safe to guide individualized tacrolimus after liver transplantation according to CYP3A5 gene polymorphism and beneficial to long-term survival for hepatocellular carcinoma recipients. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2021, 8 (3): 69-72.   Abstract （89）      PDF （2782KB）（114）       Knowledge map    Save Reference | Related Articles | Metrics

Select

The prognostic value of simple inflammation-related indexes in predicting liver transplantation for hepatocellular carcinoma Cao Yin, Wang Zhongxia, Jiang Chunping Electronic Journal of Liver Tumor    2021, 8 (3): 35-40.   Abstract （53）      PDF （1547KB）（201）       Knowledge map    Save Liver transplantation is an important treatment for hepatocellular carcinoma, but the recurrence rate remains unsatisfied. Systemic inflammatory response can be reflected by a number of common serological markers including neutrophils, lymphocytes, platelets, C-reactive protein and simple inflammatory indexes constructed by these factors. Many researches reported that these inflammatory indexes are important to predict the prognosis of HCC patients underwent liver transplantation. The purpose of this review is to summarize the published work on the prognostic value of simple inflammation based markers such as neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio, systemic immune inflammation index, prognostic nutrient index, and Glasgow prognostic score in HCC patients following liver transplantation. Reference | Related Articles | Metrics

Select

Prognostic value of four prognostic tools in end-stage primary liver cancer Yang Min, Wang Chao, Han Binbin, Sun Rui, Yu Lei, Xu Haiyan Electronic Journal of Liver Tumor    2020, 7 (3): 17-21.   Abstract （88）      PDF （1634KB）（129）       Knowledge map    Save Objective: To evaluate the prognostic value of glasgow prognostic score(GPS), prognostic nutritional index (PNI), model for end-stage liver disease(MELD) score and WPCBAL score in end-stage primary liver cancer(PLC) patients. Methods: Clinical data of 50 end-stage PLC patients discharged dead from the Cancer Hospital of the Chinese Academy of Medical Sciences between January 2010 to April 2020 were retrospectively analyzed. The general information and scores of four prognostic tools on last admission were collected. Differences of survival time among prognostic tools were compared by the log-rank test. Predictive values of various prognostic tools for 3-week mortality were evaluated by the receiver operating characteristic curve(ROC) analysis. Results: The median survival time was 9.5 days (95% CI: 6 ~15 days), and the 3-week mortality rate was 80.0%. Log-rank test showed that the survival time of MELD score≥ 15 group was shorter than MELD score < 15 group (7d vs. 16d, P = 0.002), and WPCBAL score≥ 5 group had a shorter survival time than WPCBAL score < 5 group (7d vs. 10d, P = 0.029). ROC analysis showed that the area under the ROC (AUC) of MELD score and WPCBAL score in predicting 3 week survival of patients with end-stage liver cancer were 0.7325 (95% CI: 0.5571~0.9079) and 0.6838 (95% CI: 0.5188~0.8487), respectively. Conclusion: MELD score and WPCBAL score are valuable in predicting the short-term survival status of end-stage PLC patients with low sensitivity. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 1-9.   Abstract （266）      PDF （2166KB）（236）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 48-51.   Abstract （56）      PDF （2088KB）（112）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 49-52.   Abstract （38）      PDF （4204KB）（85）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Analysis of incidence and mortality of liver cancer in Shanxi cancer registries, 2019 Guo Xuerong, Cao Ling, Zhang Ruifeng, Wang Xinchen, Qiao Nan, Zhang Yongzhen Electronic Journal of Liver Tumor    2023, 10 (2): 27-32.   Abstract （141）      PDF （2308KB）（82）       Knowledge map    Save Objective: To analyze the incidence and mortality of liver cancer in Shanxi cancer registries in 2019, and to provide the strategies of prevention and treatment of liver cancer. Method: According to the "Chinese Guideline for Cancer Registration" and referring to the data quality audit evaluation standards formulated by the International Agency for Research on Cancer (IARC)/International Association of Cancer Registration (IACR), a summary analysis was conducted on the incidence, death, and population data of liver cancer reported by tumor registration points in Shanxi Province that meet the quality control standards. The incidence/mortality crude rate, standardized incidence/mortality rate, and the cumulative rate of 0-74 years old were calculated by gender, area (urban and rural), and age. The age-standardized of Chinese standard population (ASR China) and world standard population (ASR world) were calculated by the Chinese standard population in 2000 and Segi's population, respectively. Result: In 2019, 644 new cases of liver cancer were recorded in Shanxi cancer registries, accounting for 5.39% of all new cancer cases. The crude incidence rate was 13.18 per 100 000, with ASR China of 8.13 per 100 000 and ASR world of 8.30 per 100 000, respectively. The cumulative incidence rate (0-74 years old) was 0.96%. Liver cancer was the 7th most common cancer in the registration areas of China in 2019. The incidence of ASR China was 2.46 times in males as that in females, and it was 0.99 times in urban areas as that in rural areas. A total of 791 cases died of liver cancer in Shanxi cancer registries, accounting for 10.00% of all cancer deaths. The crude mortality rate was 16.19 per 100 000, with ASR China of 9.90 per 100 000 and ASR world of 10.06 per 100 000. The cumulative mortality rate (0-74 years old) was 1.16%. Liver cancer was the 4th most common cause of cancer deaths in the registration areas of China in 2019. The mortality of ASR China was 1.90 times in males as that in females, and it was 0.78 times in urban areas as that in rural areas. The incidence and mortality of liver cancer both increased with age, and the incidence increased more significantly after the age of 40. The incidence and mortality in Shanxi Province reached the peak in the age group of 85 years, and the male was higher than the female. Conclusion: The incidence and mortality rates of liver cancer in Shanxi cancer registries are lower than national average, the male is higher than the female, and higher in rural areas than in urban areas. Therefore, the prevention and treatment of liver cancer should focus on males and pelple in rural areas. Early diagnosis and treatment of liver cancer should be promoted to increase the detection rate of early liver cancer and reduce the disease burden caused by liver cancer. Reference | Related Articles | Metrics

Select

Study on application of pain management model based on enhanced recovery after surgery in perioperative period of liver cancer Li Caiyun, Liu Yan, Guo Huanfei, Bi Yafei Electronic Journal of Liver Tumor    2020, 7 (2): 61-65.   Abstract （88）      PDF （2072KB）（156）       Knowledge map    Save Objective: To investigate the application and effect evaluation of the pain management model of of enhanced recovery after surgery(ERAS) in the perioperative period of liver cancer patients.Methods: 168 patients who underwent hepatectomy in our hospital from January 2019 to December 2019 were divided into observation group and control group according to different pain management patterns, with 86 cases in observation group and 82 cases in control group. Patients in the observation group were treated with the pain management model intervention based on ERAS during the perioperative period, while patients in the control group were treated with traditional perioperative pain management model. The differences of postoperative pain score, sleep quality, satisfaction of pain control, postoperative prophase time of getting out of bed and exhaust, hospitalization time and hospitalization expenses in the two groups were compared.Results: The postoperative pain score of the observation group was lower than that of the control group, with statistically significant difference(P<0.05). The postoperative sleep quality of the observation group was significantly better than that of the control group (P<0.05). The satisfaction degree of analgesic effect was also higher than that of the control group, with statistically significant difference (P<0.05). The postoperative prophase time of getting out of bed and exhaust and the average daily average hospitalization days of observation group were earlier than those of the control group. And the hospitalization expenses was significantly lower than that of the control group.Conclusion: The pain management model based on ERAS can effectively reduce the postoperative pain degree of liver cancer patients. After the intervention, postoperative prophase time of getting out of bed and exhaust are advanced. The postoperative recovery is faster, reducing hospitalization days. And the control of pain is more satisfactory, achieving the purpose of ERAS. Reference | Related Articles | Metrics

Select

Local therapy for unresectable intrahepatic cholangiocarcinoma Li Shupei, Yu Chenxi, Lai Fengyong, Song Peng, Du Chunxia, Yao xuesong Electronic Journal of Liver Tumor    2020, 7 (4): 44-47.   Abstract （109）      PDF （1561KB）（112）       Knowledge map    Save Intrahepatic cholangiocarcinoma refers to a malignant tumor that originates from the epithelial cells of the secondary bile duct and the branches of the intrahepatic bile duct. With the characteristics of difficult early diagnosis, high malignancy and poor prognosis. Although intrahepatic cholangiocarcinoma is relatively rare, it’s still the second most common primary malignant tumor of the liver following the hepatocellular carcinoma. In recent years, the morbidity and mortality of intrahepatic cholangiocarcinoma have been increasing. Surgical resection is currently the only radical cure, but most patients have lost the opportunity for surgery when they are diagnosed. With local treatment technology has made great progress. Those patients with unresectable intrahepatic cholangiocarcinoma, could get benefits from local treatment in terms of tumor burden reducing, symptoms relieved, prolong survival, and even transforming to surgery available. The current common local treatment methods mainly include: ablation treatment, transvascular treatment and radiotherapy. This article reviews the current status and progress of the main local treatments for intrahepatic cholangiocarcinoma. In order to get more approaches to multiple discipline therapy in intrahepatic cholangiocarcinoma. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 43-45.   Abstract （58）      PDF （1519KB）（102）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2022, 9 (4): 1-11.   Abstract （61）      PDF （1377KB）（88）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (4): 54-58.   Abstract （251）      PDF （2920KB）（244）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (2): 73-75.   Abstract （58）      PDF （5719KB）（433）       Knowledge map    Save Related Articles | Metrics